Motohide Takashi

Publications (3)6.72 Total impact

• Article: Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.

  Tatsuo Kanda, Fumio Imazeki, Shigeru Mikami, Keizo Kato, Noritomo Shimada, Yutaka Yonemitsu, Tomoo Miyauchi, Makoto Arai, Keiichi Fujiwara, Akihito Tsubota, Nobuo Takada, Takayoshi Nishino, Motohide Takashi, Nobuyuki Sugiura, Michio Kimura, Kenichi Fukai, Osamu Yokosuka
  [show abstract] [hide abstract]
  ABSTRACT: Advanced chronic hepatitis C patients with sustained virolological response by antivirals remain at risk for hepatocellular carcinoma (HCC). We investigated the incidence of HCC during and immediately after peginterferon-alfa-2a and ribavirin (RBV) treatment in patients with chronic hepatitis C in Japan. HCC was detected in 8 of 238 patients during and after these treatments (mean follow-up period: 572 ± 252 days). In conclusion, occurrence of HCC is not a rare event during and immediately after peginterferon-alfa-2a plus RBV treatment. In cases with cirrhosis, higher α-fetoprotein levels, old age, or a previous history of HCC treatment, clinicians should be especially alert for the possible development of HCC during and immediately after peginterferon-alfa-2a and RBV treatment. Clinicians should regularly check for the possible development of HCC even in chronic hepatitis C patients under treatment.
  Oncology 08/2011; 80(5-6):366-72. · 2.27 Impact Factor
• Article: Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.

  Tatsuo Kanda, Fumio Imazeki, Ryosaku Azemoto, Yutaka Yonemitsu, Shigeru Mikami, Kazuhiko Kita, Motohide Takashi, Masahiko Sunaga, Shuang Wu, Shingo Nakamoto, Akinobu Tawada, Makoto Arai, Keizo Kato, Yu Yoshida, Yoshihiro Koma, Keiichi Fujiwara, Kenichi Fukai, Noriaki Suzuki, Osamu Yokosuka
  [show abstract] [hide abstract]
  ABSTRACT: The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks. We assessed the sustained virological response (SVR) rates in HCV genotype 2-infected Japanese patients in relation to the duration of treatment. Between 2006 and 2009, among 147 patients with HCV genotype 2-infection in Chiba Prefecture, 138 consecutive patients were finally enrolled. Twenty-one, 97 and 20 patients were treated with PEG-IFN-alfa 2b plus RBV for 16, 24 and 48 weeks, respectively. Epidemiological data and treatment outcomes were retrospectively evaluated. HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0. The overall SVR rate was 82.6% (114 of 138): treatment-naïve patients, 86.4% (89 of 103); patients with history of previous treatment, 71.4% (25 of 35). Patients treated for 16, 24 and 48 weeks obtained SVR rates of 66.6% (14 of 21), 86.5% (84 of 97) and 80.0 (16 of 20), respectively. The SVR rates of PEG-IFN-alfa 2b plus RBV in Japanese patients were similar to those in previous studies. Combination treatment for 24 weeks for some patients infected with HCV genotype 2 may be superior to that for 16 weeks. More precise patient selection will be needed to shorten the combination treatment.
  Digestive Diseases and Sciences 05/2011; 56(11):3335-42. · 2.12 Impact Factor
• Article: High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study.

  Osamu Yokosuka, Shosuke Iwama, Noriaki Suzuki, Motohide Takashi, Yasuo Hirai, Katsuo Uchiumi, Michio Kimura, Nobuaki Gotou, Shinichi Hino, Akira Hayasaka, Tatsuo Kanda, Shigenobu Kawai, Kenichi Fukai, Fumio Imazeki, Hiromitsu Saisho
  [show abstract] [hide abstract]
  ABSTRACT: Hepatitis C virus (HCV) RNA titer and HCV genotype are considered to be major determinants of the outcome of interferon monotherapy. To clarify whether interferon monotherapy is really effective in patients with the appropriate viral parameters, we prospectively examined these parameters and treated the patients with interferon monotherapy. Sixty-four patients with an HCV RNA titer <100 kIU/ml and/or HCV genotype 2 were enrolled in the study. Eighteen patients with an HCV RNA titer >100 kIU/ml and genotype 1 were also enrolled as controls. All patients were treated with 10 megaunits of interferon-alpha2b every day for 2 weeks and then 3 times a week for 24 weeks. Of the 64 patients with either HCV RNA <100 kIU/ml and/or genotype 2, seven dropped out from the study. Of the remaining 57 who completed the treatment, 48 (84%) showed a virologic sustained response. In contrast, only 4 of the 18 patients (22%) with HCV RNA >100 kIU/ml and genotype 1 were virologic sustained responders (p < 0.001). Our current study showed that the patients with HCV RNA <100 kIU/ml and/or HCV genotype 2 are good candidates for interferon monotherapy.
  Intervirology 47(6):328-34. · 2.34 Impact Factor